1. Approaches in Newly Diagnosed Multiple Myeloma: When and What

2. Program Goals

3. Case 1

5. Diagnostic Criteria Multiple Myeloma Requiring Therapy

6. IMWG Cytogenetic Risk Features

7. Components of Myeloma Therapy Transplant Eligible Patients

8. Role of Early ASCT in MM

9. ASCT in MM Today By the Numbers

10. IFM 2013-04 VTD vs Bortezomib, Cyclophosphamide, Dex

11. Role of MRD Testing in MM

12. MRD Assessment

13. IFM 2009 Study

14. MM Biology and Treatment Race/Ethnicity

15. EMN02/HO95 VMP vs Single ASCT or Double ASCT

16. STaMINA Trial BMT CTN 0702

17. Allogeneic SCT

18. Monitoring

19. Key Takeaways Newly Diagnosed Transplant Eligible

20. Case 2

21. Smoldering Myeloma 2014 IMWG Criteria

23. Case 2 (cont) 4 years later

24. Selecting Therapy

25. SWOG S0777 VRD vs Rd

26. FIRST Trial Continuous Rd vs Rd-18 vs MPT

27. Components of Myeloma Therapy Transplant Ineligible Patients

28. FIRST Trial Continuous and Fixed-Cycle RD

29. Monitoring

30. Future Directions

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)